The biological variation of testosterone and sex hormone-binding globulin (SHBG) in polycystic ovarian syndrome: Implications for SHRG as a surrogate marker of insulin resistance

V. Jayagopal, E. S. Kilpatrick, P. E. Jennings, D. A. Hepburn, Stephen Atkin

Research output: Contribution to journalArticle

105 Citations (Scopus)

Abstract

This study was designed to assess the biological variability of total testosterone and SHBG in polycystic ovarian syndrome (PCOS) and to determine the use of SHBG as a surrogate marker of insulin resistance in PCOS. Fasting blood samples were collected at 4-d intervals on 10 consecutive occasions from 12 PCOS patients and 11 age- and weight-matched controis. Duplicate samples were analyzed for SHBG, testosterone, and insulin in a single batch, and insulin resistance was calculated by the homeostasis model assessment method (HOMA-IR). The PCOS group had higher testosterone (mean ± SD, 3.9 ± 0.8 vs. 3.2 ± 1.3 nmol/liter; P = 0.001), lower SHBG (28.6 ± 17.1 vs. 57.6 ± 30.2 nmol/liter; P = 0.001), and greater HOMA-IR (5.85 ± 5.3 vs. 1.67 ± 0.63 U; P = 0.001) than the controls. In contrast to HOMA-IR (1.09 vs. 0.48 U; P = 0.001), the intra-individual variation in SHBG was lower in the PCOS group (mean, 3.4 vs. 6.3 nmol/liter; P = 0.041). The index of individuality for SHBG and testosterone in PCOS was 0.49 and 0.69, respectively. This study shows that for patients with PCOS, SHBG is an integrated marker of insulin resistance that may be of use to identify insulin-resistant individuals for targeted treatment with insulin-sensitizing agents. However, SHBG and testosterone concentrations measured in isolation are inherently unsuitable for use as tests to detect hyperandrogenemia.

Original languageEnglish
Pages (from-to)1528-1533
Number of pages6
JournalJournal of Clinical Endocrinology and Metabolism
Volume88
Issue number4
DOIs
Publication statusPublished - 1 Apr 2003
Externally publishedYes

Fingerprint

Sex Hormone-Binding Globulin
Polycystic Ovary Syndrome
Insulin Resistance
Testosterone
Biomarkers
Insulin
Individuality
Fasting
Homeostasis
Blood
Weights and Measures

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

The biological variation of testosterone and sex hormone-binding globulin (SHBG) in polycystic ovarian syndrome : Implications for SHRG as a surrogate marker of insulin resistance. / Jayagopal, V.; Kilpatrick, E. S.; Jennings, P. E.; Hepburn, D. A.; Atkin, Stephen.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 88, No. 4, 01.04.2003, p. 1528-1533.

Research output: Contribution to journalArticle

@article{e0aa2c728e604fc9b0877930f9a68dc4,
title = "The biological variation of testosterone and sex hormone-binding globulin (SHBG) in polycystic ovarian syndrome: Implications for SHRG as a surrogate marker of insulin resistance",
abstract = "This study was designed to assess the biological variability of total testosterone and SHBG in polycystic ovarian syndrome (PCOS) and to determine the use of SHBG as a surrogate marker of insulin resistance in PCOS. Fasting blood samples were collected at 4-d intervals on 10 consecutive occasions from 12 PCOS patients and 11 age- and weight-matched controis. Duplicate samples were analyzed for SHBG, testosterone, and insulin in a single batch, and insulin resistance was calculated by the homeostasis model assessment method (HOMA-IR). The PCOS group had higher testosterone (mean ± SD, 3.9 ± 0.8 vs. 3.2 ± 1.3 nmol/liter; P = 0.001), lower SHBG (28.6 ± 17.1 vs. 57.6 ± 30.2 nmol/liter; P = 0.001), and greater HOMA-IR (5.85 ± 5.3 vs. 1.67 ± 0.63 U; P = 0.001) than the controls. In contrast to HOMA-IR (1.09 vs. 0.48 U; P = 0.001), the intra-individual variation in SHBG was lower in the PCOS group (mean, 3.4 vs. 6.3 nmol/liter; P = 0.041). The index of individuality for SHBG and testosterone in PCOS was 0.49 and 0.69, respectively. This study shows that for patients with PCOS, SHBG is an integrated marker of insulin resistance that may be of use to identify insulin-resistant individuals for targeted treatment with insulin-sensitizing agents. However, SHBG and testosterone concentrations measured in isolation are inherently unsuitable for use as tests to detect hyperandrogenemia.",
author = "V. Jayagopal and Kilpatrick, {E. S.} and Jennings, {P. E.} and Hepburn, {D. A.} and Stephen Atkin",
year = "2003",
month = "4",
day = "1",
doi = "10.1210/jc.2002-020557",
language = "English",
volume = "88",
pages = "1528--1533",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "4",

}

TY - JOUR

T1 - The biological variation of testosterone and sex hormone-binding globulin (SHBG) in polycystic ovarian syndrome

T2 - Implications for SHRG as a surrogate marker of insulin resistance

AU - Jayagopal, V.

AU - Kilpatrick, E. S.

AU - Jennings, P. E.

AU - Hepburn, D. A.

AU - Atkin, Stephen

PY - 2003/4/1

Y1 - 2003/4/1

N2 - This study was designed to assess the biological variability of total testosterone and SHBG in polycystic ovarian syndrome (PCOS) and to determine the use of SHBG as a surrogate marker of insulin resistance in PCOS. Fasting blood samples were collected at 4-d intervals on 10 consecutive occasions from 12 PCOS patients and 11 age- and weight-matched controis. Duplicate samples were analyzed for SHBG, testosterone, and insulin in a single batch, and insulin resistance was calculated by the homeostasis model assessment method (HOMA-IR). The PCOS group had higher testosterone (mean ± SD, 3.9 ± 0.8 vs. 3.2 ± 1.3 nmol/liter; P = 0.001), lower SHBG (28.6 ± 17.1 vs. 57.6 ± 30.2 nmol/liter; P = 0.001), and greater HOMA-IR (5.85 ± 5.3 vs. 1.67 ± 0.63 U; P = 0.001) than the controls. In contrast to HOMA-IR (1.09 vs. 0.48 U; P = 0.001), the intra-individual variation in SHBG was lower in the PCOS group (mean, 3.4 vs. 6.3 nmol/liter; P = 0.041). The index of individuality for SHBG and testosterone in PCOS was 0.49 and 0.69, respectively. This study shows that for patients with PCOS, SHBG is an integrated marker of insulin resistance that may be of use to identify insulin-resistant individuals for targeted treatment with insulin-sensitizing agents. However, SHBG and testosterone concentrations measured in isolation are inherently unsuitable for use as tests to detect hyperandrogenemia.

AB - This study was designed to assess the biological variability of total testosterone and SHBG in polycystic ovarian syndrome (PCOS) and to determine the use of SHBG as a surrogate marker of insulin resistance in PCOS. Fasting blood samples were collected at 4-d intervals on 10 consecutive occasions from 12 PCOS patients and 11 age- and weight-matched controis. Duplicate samples were analyzed for SHBG, testosterone, and insulin in a single batch, and insulin resistance was calculated by the homeostasis model assessment method (HOMA-IR). The PCOS group had higher testosterone (mean ± SD, 3.9 ± 0.8 vs. 3.2 ± 1.3 nmol/liter; P = 0.001), lower SHBG (28.6 ± 17.1 vs. 57.6 ± 30.2 nmol/liter; P = 0.001), and greater HOMA-IR (5.85 ± 5.3 vs. 1.67 ± 0.63 U; P = 0.001) than the controls. In contrast to HOMA-IR (1.09 vs. 0.48 U; P = 0.001), the intra-individual variation in SHBG was lower in the PCOS group (mean, 3.4 vs. 6.3 nmol/liter; P = 0.041). The index of individuality for SHBG and testosterone in PCOS was 0.49 and 0.69, respectively. This study shows that for patients with PCOS, SHBG is an integrated marker of insulin resistance that may be of use to identify insulin-resistant individuals for targeted treatment with insulin-sensitizing agents. However, SHBG and testosterone concentrations measured in isolation are inherently unsuitable for use as tests to detect hyperandrogenemia.

UR - http://www.scopus.com/inward/record.url?scp=0038699027&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038699027&partnerID=8YFLogxK

U2 - 10.1210/jc.2002-020557

DO - 10.1210/jc.2002-020557

M3 - Article

C2 - 12679434

AN - SCOPUS:0038699027

VL - 88

SP - 1528

EP - 1533

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 4

ER -